The New Jersey Supreme Court on Wednesday said more than 500 lawsuits filed against pharmaceutical giant Hoffmann-La Roche by users of the acne drug Accutane—who allege the drug caused them to develop inflammatory bowel disease—should be dismissed because of the state’s strong public policy toward protecting drugmakers who follow federal Food and Drug Administration rules.

In a unanimous ruling, the court said an appeals court erred when it overturned a trial judge’s decision to dismiss the lawsuits.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]